Form 4 for ELOX Eloxx Pharmaceuticals, Inc.

Accepted 2026-06-17 17:15:00 ET · period of report 2026-06-10 · accession 0000919574-26-004021 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DMI	2026-06-17 17:15	2026-06-10	ELOX	Domicilium Real Estate Fund III LP	10%	J - Other	—	+600.0K	361.6K	New	—
DMI	2026-06-17 17:15	2026-06-10	ELOX	Domicilium Real Estate Fund III LP	10%	J - Other	—	+600.0K	834.5K	+256%	—

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	common stock, $0.01 par value per share	2026-06-10	J	A	238,422	—	238,422	I See footnote	—	—	(F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F2) The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
2	Common	common stock, $0.01 par value per share	2026-06-10	J	A	361,578	—	361,578	I See footnote	—	—	(F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F3) The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.
3	Derivative	Pre-funded Warrant	2026-06-10	J	A	238,422	—	0	I See footnote	— · — to —	238,422 common stock, $0.01 par value per share	(F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F2) The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
4	Derivative	Pre-funded Warrant	2026-06-10	J	A	361,578	—	834,489	I See footnote	— · — to —	361,578 common stock, $0.01 par value per share	(F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. (F3) The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.